Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexosome
- Development stage
- Unknown
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Dexosome** is a cell-free therapeutic vaccine derived from dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) for cancer immunotherapy. It leverages exosomes secreted by DCs to present antigens, activating both adaptive (T lymphocytes) and innate (natural killer cells) immune responses against tumors. Dexosomes have demonstrated antitumor activity in preclinical mouse models and safety in human clinical trials, including phase I studies in advanced non-small cell lung carcinoma (NSCLC) and phase II in malignant melanoma, without significant adverse effects.[2][5]
- Other names
- dexosomes
02
Targets
NKG2D (Natural killer group 2 member D receptor)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on Dexosome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dexosome.